Filing Details

Accession Number:
0001209191-11-043274
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-08-09 19:47:21
Reporting Period:
2011-08-05
Filing Date:
2011-08-09
Accepted Time:
2011-08-09 19:47:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
353569 Quidel Corp QDEL In Vitro & In Vivo Diagnostic Substances (2835) 942573850
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1021412 W Jack Schuler 10165 Mckellar Court
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-08-05 20,865 $14.07 3,168,153 No 4 P Direct
Common Stock Acquisiton 2011-08-08 79,135 $14.00 3,247,288 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. The shares reported on this Form 4 were purchased by the Jack W. Schuler Living Trust.
  2. The weighted average purchase price for these transactions was $14.0733 per share, with a range of $13.96 to $14.10 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price.
  3. In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 683,843 shares are held indectrly by trusts for the benefit of the Reporting Person's children. The Reporting Person disclaims all beneficial ownership of the shares owned by his sposue and the trusts for the benefit of his children, except to the extent of his pecuniary interest, if any.
  4. The weighted average purchase price for these transactions was $13.995 per share, with a range of $13.51 to $14.92 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price.